Home › Calculator › ALNY Dividend Calculator 2026
ALNY Dividend DRIP Calculator 2026
0.89% YieldHealthcareAlnylam Pharmaceuticals, Inc. · NASDAQ
Price: $223.85 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When ALNY pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your ALNY snowball 📈
$10,000 in ALNY → $10.33M in 10 years · $7.51/month
About Alnylam Pharmaceuticals, Inc. (ALNY) — Dividend Analysis 2026
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.
Compare ALNY with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full ALNY DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open ALNY position with:
🌍 ALNY Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold ALNY.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 0.89% | -1.91% | $89 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 0.76% | -2.04% | $76 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 0.71% | -2.09% | $71 / yr |
| 🇬🇧 UK ISA | 0% | 0.89% | -1.91% | $89 / yr |
| 🇬🇧 UK Taxable | 8.75% | 0.81% | -1.99% | $81 / yr |
| 🇨🇦 TFSA | 0% | 0.89% | -1.91% | $89 / yr |
| 🇨🇦 CA Taxable | 25% | 0.67% | -2.13% | $67 / yr |
| 🇦🇺 Super (pension) | 15% | 0.76% | -2.04% | $76 / yr |
| 🇦🇺 AU Taxable | 30% | 0.62% | -2.18% | $62 / yr |
| 🇩🇪 DE Taxable | 26.375% | 0.66% | -2.14% | $66 / yr |
| 🇫🇷 FR Taxable | 30% | 0.62% | -2.18% | $62 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 ALNY Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 ALNY Dividend Payment Schedule
ALNY pays quarterly — 4 times per year. Next ex-div: TBD.
📊 ALNY vs Healthcare Benchmarks
How ALNY compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for ALNY sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ ALNY Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| M-Exempt | 2026-06-01 | 3,830 | — | — | ||
| Sale | 2026-06-01 | 921 | $297.71 | $274.2K | ||
| Sale | 2026-06-01 | 1,175 | $298.91 | $351.2K | ||
| Sale | 2026-06-01 | 1,222 | $299.87 | $366.4K | ||
| Sale | 2026-06-01 | 495 | $300.72 | $148.9K | ||
| Sale | 2026-06-01 | 17 | $302.65 | $5.1K | ||
| M-Exempt | 2026-06-01 | 3,830 | $70.20 | $268.9K | ||
| A-Award | 2026-06-01 | 4,393 | $295.63 | $1.30M | ||
| A-Award | 2026-05-20 | 671 | — | — | ||
| A-Award | 2026-05-20 | 1,441 | $298.48 | $430.1K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Geographic Revenue Breakdown
Where ALNY earns its moneyRevenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the ALNY dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Alnylam Pharmaceuticals, Inc. (ALNY) is currently trading at $223.85, 51% below its 52-week high. The current dividend yield is 0.89% based on an annual payout of $2.00 per share.
ALNY (Alnylam Pharmaceuticals, Inc.) — 0.89% Dividend Yield Analysis
Alnylam Pharmaceuticals, Inc. (ALNY) is a healthcare stock currently trading at $223.85 with a dividend yield of 0.89%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Dividend payments are not guaranteed and can be reduced or suspended at any time.
Auto-generated from live market data. For educational purposes only — not financial advice.